share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-10% Owner Cormorant Asset Management, LP

EyePoint Pharmaceuticals | 4：持股變動聲明-股東 Cormorant Asset Management, LP
美股SEC公告 ·  05/09 05:03
牛牛AI助理已提取核心訊息
Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP has completed the purchase of shares in EyePoint Pharmaceuticals, Inc. (EYPT) on May 6, 2024. The transactions were executed in the open market with a total of 850,000 shares acquired. The first transaction involved the purchase of 642,847 shares at a price of $11.70 per share, while the second transaction saw 207,153 shares bought at $12.36 each. Following these transactions, Cormorant Asset Management's indirect beneficial ownership in EyePoint Pharmaceuticals totals 8,325,000 shares. The nature of the indirect beneficial ownership is detailed in a footnote not provided in this summary.
Cormorant Asset Management, LP已於2024年5月6日完成了對EyePoint Pharmicals, Inc.（埃及）股份的收購。這些交易在公開市場上執行，共收購了85萬股股票。第一筆交易涉及以每股11.70美元的價格購買642,847股股票，而第二筆交易以每股12.36美元的價格購買了207,153股股票。這些交易之後，Cormorant資產管理公司對EyePoint Pharmicals的間接實益所有權共計8,325,000股。本摘要中未提供的腳註詳細說明了間接受益所有權的性質。
Cormorant Asset Management, LP已於2024年5月6日完成了對EyePoint Pharmicals, Inc.（埃及）股份的收購。這些交易在公開市場上執行，共收購了85萬股股票。第一筆交易涉及以每股11.70美元的價格購買642,847股股票，而第二筆交易以每股12.36美元的價格購買了207,153股股票。這些交易之後，Cormorant資產管理公司對EyePoint Pharmicals的間接實益所有權共計8,325,000股。本摘要中未提供的腳註詳細說明了間接受益所有權的性質。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。